<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559114</url>
  </required_header>
  <id_info>
    <org_study_id>0785</org_study_id>
    <nct_id>NCT03559114</nct_id>
  </id_info>
  <brief_title>PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)</brief_title>
  <acronym>PROTEST</acronym>
  <official_title>PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study, phase III, multi-centre, double blind, randomized controlled trial of
      patients with traumatic brain injury (TBI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe brain injury are at risk for developing blood clots in their legs, which
      can travel to the lungs. This potentially serious complication is known as venous
      thromboembolism (VTE). Anticoagulants are commonly used to prevent VTE in hospital patients.
      However, in patients with major head injury, anticoagulant prevention is commonly delayed for
      the fear that it can potentially lead to further bleeding in the brain. Another method that
      aims to prevent blood clots involves the use of sequential compression device (SCD) that
      compress the legs and increase the flow of blood in the leg veins.

      This study will compare results from patients who receive the SCDs only to those who receive
      both SCD and anticoagulants. The outcome of this study will provide information about how
      best to prevent blood clots while not increase brain bleeding after head injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically important VTE</measure>
    <time_frame>8 days</time_frame>
    <description>Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of:
Symptomatic, objectively-confirmed pulmonary embolism (PE), or
Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or
Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically-important ICB (Intracranial bleeding) progression</measure>
    <time_frame>7 days</time_frame>
    <description>Clinically-important ICB progression within 7±1 days after randomization , as defined by having (1) any increase in volume of blood in the brain on any CT scan within 7±1 days relative to initial CT scan on Day 0* AND (2) clinical worsening within 24 hours of this CT scan, defined by one or more of the following:
Surgical intervention related to increased ICB after Day 0 (craniotomy/craniectomy, ICP monitor, external ventricular drain)
Decrease of GCS (Glasgow Coma Scale) by at least 2 points not related to sedation
Increase in ICP &gt;5 mmHg on 2 occasions at least 6 hours apart despite medical therapy (if ICP monitor is in place)
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objectively confirmed new or progressing ICB on radiology,</measure>
    <time_frame>8 days</time_frame>
    <description>Assessed by comparing the initial brain CT (Day 0) to that performed within 8±1 days following randomization (or most recent prior to death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180-day Mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Mortality at 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day Mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Mortality at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed VTE after day 7</measure>
    <time_frame>30 days</time_frame>
    <description>Any clinically important VTE occurring between Day 8 to Day 30 detected by treating clinicians</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcome at day 30 as measured by Glasgow Outcome Scale Extended</measure>
    <time_frame>30 days</time_frame>
    <description>Glasgow Outcome Scale Extended (GOSE) at Day 30±5 by phone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcome at day 180 as measured by Glasgow Outcome Scale Extended</measure>
    <time_frame>180 days</time_frame>
    <description>Glasgow Outcome Scale Extended (GOSE) at Day 180±14 by phone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome at 30 days as measured by the EuroQol5D</measure>
    <time_frame>30 days</time_frame>
    <description>EQ-5D (EuroQol 5D) at Day 30±5 by phone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome at 180 days as measured by the EuroQol5D</measure>
    <time_frame>180 days</time_frame>
    <description>EQ-5D (EuroQol 5D) at Day 180±14 by phone interview.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Anticoagulant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.</description>
    <arm_group_label>Anticoagulant</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline in prophylactic doses administered daily if screening criteria are satisfied.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe acute TBI defined as GCS ≤8 and within 48 hours of injury ;

          -  ≥ 16 years of age (with exception of Quebec where patients will be ≥ 18 years of age)

        Exclusion Criteria:

          -  Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl
             alcohol or to other low molecular weight heparins and/or heparins or pork products

          -  Known history of confirmed or suspected immunologically-mediated heparin-induced
             thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a
             known history of a positive in vitro platelet-aggregation test in the presence of
             FRAGMIN (Dalteparin) is positive

          -  Known septic endocarditis

          -  Uncontrollable active bleeding

          -  Known major blood clotting disorders

          -  Known acute gastroduodenal ulcer (with active bleeding)

          -  Severe uncontrolled hypertension (i.e. BP&gt;210 despite medications)

          -  Known diabetic or hemorrhagic retinopathy

          -  Confirmed complete acute spinal cord injury

          -  Unable to receive bilateral SCDs due to femur fracture, below-knee injury requiring
             external fixation device, critical lower leg ischemia

          -  Unstable pelvic fracture requiring external or internal fixation

          -  Presence of another confounding factor that can adequately explain the poor GCS at
             time of presentation (e.g. drug toxicity, seizure).

          -  Known presence of irreversible coagulopathies

          -  Known Pregnancy

          -  Participants extremely low weight (&lt;45 kg), or extremely high weight (&gt;120kg)

          -  Not expected to survive more than 48 hours from admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Pirouzmand, MD, MSc, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damon Scales, MD, PhD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farhad Pirouzmand, MD, MSc, FRCSC</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>5263</phone_ext>
    <email>farhad.pirouzmand@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catarina Downey, MSc, CCRP</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>87546</phone_ext>
    <email>protest@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Ruddell</last_name>
      <email>Stacy.Ruddell@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Andreas Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrica Thompson</last_name>
      <email>patrica.thompson@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tayne Hewer</last_name>
      <email>tayne.hewer@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Kutsogiannis, MD, MHS, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrica Thompson</last_name>
      <email>patrica.thompson@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tayne Hewer</last_name>
      <email>tayne.hewer@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Kutsogiannis, MD, MHS, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Foster</last_name>
      <email>denise.foster@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Donald Griesdale, MD, MPH, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura-Lee Magennis</last_name>
      <email>Laura.Magennis@nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Julien</last_name>
      <email>lisa.julien@nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sean Christie, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurel Murphy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Martyniuk</last_name>
      <email>martynia@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Sunjay Sharma, MD, MSc, FRCSC, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Engels, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7N 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Boyd</last_name>
      <email>Tracy.Boyd@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Gordon Boyd, MD, PhD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>KIH 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Porteous</last_name>
      <email>rporteous@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sydney Mietzitis</last_name>
      <email>smiezitis@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Shane English, MD, MSc, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Farhad Pirouzmand, MD, MSc, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damon Scales, MD, PhD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Nagaraj</last_name>
      <email>rashmi.nagaraj@usask.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lilian Urroz</last_name>
      <email>lilian.urroz@usask.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Hunter, MD, FRCPC, CSCN (EEG)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sequential Compression Device</keyword>
  <keyword>Anticoagulant Thromboprophylaxis</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Sub Cutaneous</keyword>
  <keyword>VTE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

